Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Windlas Biotech Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹460
Per ShareLot Size
30 Shares
Minimum Investment
₹13,800
Issue Size
₹395.36 Cr
Face Value
₹5
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
70.2%
Issue Type
Book Building
ISIN
INE0H5O01029
Windlas Biotech Ltd is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices ("GMP") with a focus on improved safety, efficacy and cost.
Pharmaceutical companies are increasingly outsourcing development and manufacturing of new products. Domestic formulations CDMO is projected to grow at a CAGR of approximately 14% between Fiscals 2020 and 2025. The key drivers for growth in the CDMO industry include growth of asset light pharmaceutical companies, increasing cost awareness and manufacturing efficiency, growing focus on product/ packaging innovation, enabling customer's end market aspirations through combinations products and new dosages, end-to-end service, time to market, maintaining margins, increasing generics and institutionalization of pharmaceutical industry, regulatory changes and increasing economies of scale shifting CDMO identity from `supplier' to `partner' status.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial Public Offer of 8,729,023* equity shares of face value of Rs.5 each ("equity shares") of Windlas Biotech Limited ("company" Rs.455 per equity share) aggregating to Rs.401.54 Crores (the "offer") comprising a fresh issue of 3,586,956* equity shares aggregating to Rs.165 Crores (the "fresh issue") and an offer for sale of 5,142,067* equity shares, comprising of 1,136,000* equity shares aggregating to Rs.52.26* Crores by Vimla Windlass (the "individual selling shareholder") and 4,006,067* equity shares aggregating to Rs.184.28* Crores by Tano India Private Equity Fund II (the "investor selling shareholder", and collectively with the individual selling shareholder, the "selling shareholders", and such equity shares, the "offered shares") aggregating to Rs.236.54 Crores (the "offer for sale). The offer constitutes 40.05% of the post-offer paid-up equity share capital of the Company. The face value of equity shares is Rs.5 each. The offer price is Rs.460 per equity share and is 92 times the face value of the equity shares. *subject to finalisation of the basis of allotment.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Windlas Biotech Ltd was incorporated on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by the Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana, at New Delhi ("RoC Delhi"). The Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The registered office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by its Shareholders on August 22, 2009. The alteration with respect to the place of the registered office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by its Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand at Kanpur on July 22, 2016. Our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021, consequent upon change of name on conversion to a public limited company was granted by the Registrar of Companies, Uttarakhand at Dehradun ("RoC").
Wholesalers and Retailers
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.